X

BioCanCell Announces Exploration of Funding Round Conditioned on a Going Private Transaction and Business Development Update

  Jerusalem, Israel, October 30, 2017, (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE: BICL), a clinical-stage…

admin

BioCancell Advances Intellectual Property Portfolio in the U.S.

Jerusalem, Israel, November 5, 2015, BioCancell Ltd. (TASE: BICL), a clinical-stage biopharmaceutical company focused on…

admin

Biocancell advances phase III clinical program for bladder cancer

Jerusalem, Israel, October 1, 2015, BioCancell Ltd. (TASE: BICL), a clinical-stage biopharmaceutical company focused on…

admin

Biocancell receives FDA fast track designation for BC-819 for treatment of bladder cancer patients

Jerusalem, Israel, September 10, 2015, BioCancell Ltd. (TASE: BICL), a clinical-stage biopharmaceutical company focused on…

admin

Biocancell announces development of new diagnostic product BC-830

BioCancell Ltd. today announced that it has begun developing a new product, designated BC-830, for…

admin

BioCancell Files International Patent Request For New Drug Formulation

Jerusalem, Israel -- BioCancell Ltd. (TASE:BICL) today announced that it had filed an international patent…

admin

BioCancell Receives Outline Approval for Two Phase III Bladder Cancer Trials

Jerusalem, Israel -- BioCancell Ltd. (TASE:BICL) is pleased to announce that, following discussions held over…

admin

BioCancell Announces Results of Bladder Cancer Trial

Jerusalem, Israel -- BioCancell Ltd. (TASE:BICL) announced today the results of a bladder cancer clinical…

admin

BioCancell Announces Final Phase IIb Bladder Cancer Trial Results

Jerusalem, Israel -- BioCancell Ltd. (TASE:BICL) today announced final results in its Phase IIb bladder cancer clinical…

admin

BioCancell Announces First-Stage Phase IIb Pancreatic Cancer Trial Results

Jerusalem, Israel -- BioCancell Ltd. (TASE:BICL) today announced first-stage results in its Phase IIb pancreatic cancer clinical…

admin